CWY – Credit Suisse rates the stock as Underperform
Credit Suisse downgrades to Underperform from Neutral and reduces the target to $2.60 from $2.80.
Read MoreCredit Suisse downgrades to Underperform from Neutral and reduces the target to $2.60 from $2.80.
Read MoreThe broker retains its Hold rating and notes the potential for a takeover price to exceed the current share price. Separately, the analyst raises its stand-alone valuation for the company to $6.47/share from $6.41.
Read MoreThe broker observes retail is relatively more defensive as an asset class in cyclical downturns and as a result upgrades to Neutral from Underperform. Target is reduced to $2.79 from $2.85.
Read MoreCredit Suisse raises its target price for Atlas Arteria to $8.60 from $7.10 after media reports that IFM Investors is seeking to increase its shareholding to 15% from 7.94% at an $8.10 offer price.
Read MoreThe Outperform rating and $2.50 target are retained.
Read MoreNeutral maintained. Target is reduced to $71.66 from $87.80.
Read MoreThe target price slips to $16.38 from $16.98, while the add rating is maintained.
Read MoreBuy rating and $13.50 target price retained.
Read MoreThe broker reduces the target to $39 from $40 and retains an Outperform rating.
Read MoreNeutral rating maintained. Target is reduced to $85 from $86.
Read MoreThe target price falls to $4.30 from $5.15 and the Add rating is maintained.
Read MoreThe broker sticks with Outperform, while an increase in the assumed risk-free rate cuts the target to $3.94 from $4.27.
Read MoreDespite the shares looking “expensive” at face value (high PE multiple), UBS sees an attractive entry point, also reflected in its Buy rating. Target $34.60 (was $35.90).
Read MoreMorgans initiates coverage on ‘one of the highest performing lotteries businesses in the world’ the Lottery Corp with an Add rating and $5.40 target price.
Read MoreBuy rating retained, UBS pegging Worley as an energy transition winner offering a 10-year EPS compound annual growth rate of 10%. Target price rises to $16.40 from $14.40.
Read MoreThe Hold rating is retained, while the target price falls by -8% to $6.17.
Read MoreThe Neutral rating is retained and the target price decreases to $0.23 from $0.29.
Read MoreOutperform rating retained. Target price rises to $1.85 from $1.75.
Read MoreThe broker downgrades to Underperform from Neutral. Target price falls to $19 from $32.
Read MoreThe Buy rating and target price of $56.00 are retained.
Read MoreTarget price shifts to $7.30. Hold rating retained.
Read MoreUBS has returned – “initiation” – with a Buy rating and $30.50 price target.
Read MoreTarget price steady at $2.15. Buy rating retained.
Read MoreThe Underperform rating and target price of $6.60 are retained.
Read MoreThe Outperform rating is retained and the target price increases to $0.34 from $0.27.
Read MoreThe target price, lowered to $14.40 from $16.70, is still well in advance of the current share price and the Add rating is retained.
Read MoreThe Outperform rating and target price of $1.20 are retained.
Read MoreCredit Suisse retains its Outperform rating and $4.90 target.
Read MoreAmong the domestic insurers, the broker continues to prefer Buy-rated Suncorp Group over Insurance Australia Group ((IAG)). The $14.40 target price is retained for the former.
Read MoreCiti retains a Buy rating and $5.50 target price.
Read MoreThe Add rating and $1.37 target price are retained.
Read MoreBuy rating retained. Target price falls to NZ$24 from NZ$25.75.
Read MoreThe Outperform rating is retained and the target price decreases to $14.50 from $14.70.
Read MoreThe broker maintains its Add rating and $5.43 target price.
Read MoreThe Outperform rating is retained and the target price decreases to $1.00 from $1.10.
Read MoreMorgans maintains its Add rating and raises its target price to $8.21 from $8.14.
Read MoreDowngrade to Neutral from Outperform, target falls to $4.15 from $4.30.
Read MoreThe Add rating is retained, while the target falls to $4.45 from $4.56.
Read MoreThe Outperform rating is retained and the target price decreases to $2.20 from $2.40.
Read MoreUBS maintains a Neutral rating. Target price eases to $31.80 from $32.20
Read More